Miguel Ángel Climent Durán-rekin lankidetzan egindako argitalpenak (7)

2016

  1. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593

2014

  1. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647

2010

  1. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet, Vol. 375, Núm. 9712, pp. 377-384

2009

  1. Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study

    Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314

2004

  1. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

    Annals of Oncology, Vol. 15, Núm. 9, pp. 1358-1365

2002

  1. Dynamic filters for the spectral analysis of random signals

    Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551

  2. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period

    Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743